The second example involves the BCL-2/BCL-XL dual inhibitor navitoclax (ABT-263) and the BCL-2-specific inhibitor venetoclax (ABT-199), which are designed to treat patients with relapsed or refractory chronic lymphocytic leukemia (Figure 19). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.